80 results about "Cancer targeting" patented technology

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and / or functional groups which have utility in imaging and targeted cancer therapy.

The application provides guidance and navigation control (GNC) proteins. In one embodiment, the GNC protein Comprises a T-cell binding moiety and a cancer-targeting moiety, wherein the T-cell binding moiety has a binding specificity to a T-cell receptor comprising CD3, CD28, PDL1, PD1, OX40, 4-1BB, GITR, TIGIT, TIM-3, LAG-3, CTLA4, CD40, VISTA, ICOS, BTLA, Light, NKp30, CD28H, CD27, CD226, CD96, CD112R, A2AR, CD160, CD244, CECAM1, CD200R, TNFRSF25 (DR3), or a combination thereof, and wherein the cancer targeting moiety has a binding specificity to a cancer cell receptor.

Disclosed are: an albumin-binding prodrug that can stably and selectively bind to albumin capable of targeting cancer while also stably binding to drugs; an albumin-drug conjugate in which the albumin-binding prodrug is bound to albumin; a method for preparing the albumin-drug conjugate; and a pharmaceutical composition for preventing or treating cancer, comprising the albumin-binding prodrug or the albumin-drug conjugate.

Provided is the use of a genetically engineered phage expressing a first peptide targeting a Programmed Cell Death protein 1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) and a second peptide targeting a cancer-related antigen for enhanced efficacy in cancer treatment. Thus, provided are methods for improved anti-cancer therapy, especially in the treatment of solid tumors, by using a recombinant phage that is capable of specifically targeting the PD-1 / PD-L1 pathway and specifically targeting a cancer antigen, as well as compositions and kits useful for such treatment methods.

Recombinant polynucleotides and vectors containing an engineered (artificial) exon-intron-exon gene structure in a transgene are provided, which undergoes splicing when it is expressed in a target cell.

The invention discloses a spiro derivative serving as a WRN helicase inhibitor and application of the spiro derivative. The spiro derivative has better WRN helicase inhibitory activity, can be used for inhibiting growth of microsatellite unstable (MSI) tumor cells by inhibiting high-level DNA double-strand breakage (DSB) in microsatellite unstable (MSI) cells caused by WRN, is used for preventing and / or treating related cancers, especially colorectal cancer, gastric cancer, ovarian cancer, endometrial tumor and the like, and has a good application prospect. The vacancy of specific MSI type cancer targeting drugs can be filled, and the application prospect and value in the field of medicines are very good.

Provided herein is a composition comprising, a cell, comprising nucleic acids encoding a chimeric antigen receptor (CAR) and one or more of signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax and HTLV2-Tax, wherein the CAR comprises an a) extracellular antigen specific domain, b) a transmembrane domain and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); wherein c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more co-stimulatory domains. Also provided herein are methods for treating diseases using the compositions described herein. Further provided herein is a kinase inhibitor for use in therapeutic methods described herein.

The present invention relates to a novel extracellular vesicle linked to an anti-TfR1 antibody and to a use thereof. An extracellular vesicle, according to one aspect, exhibits excellent delivery capability to tumor cells and activates immune cells, thereby being effectively usable as a targeted anticancer therapeutic not limited to specific cancer types.

The present invention relates to compounds and scaffolds for targeting fibroblast activating protein (FAP) in cancer-associated fibroblasts (CAF). The scaffold comprises a (4-quinolylcarbonyl) glycyl-2-cyanopyrrolidine scaffold, the 8-position of the quinolylcarbonyl moiety of which is substituted by a bridging carbon atom or oxygen atom, as shown in formula (I). # imgabs0 # wherein X represents CH2 or O; r1 represents H, Me, CH (CH3) C2H5, CH2CH (CH3) 2, CH (CH3) 2, CH2OH, CH2SH, CH (OH) CH3, CH2C (O) NH2, CH2CH2C (O) NH2, (CH2) mCO2H, (CH2) mNH2, where m is from 1 to 4; and R2 and R3 each independently represent H or F.

A compound derivative is provided, where R in the compound of formula A is piperidine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

To provide a method for treating the target cancer. [Solution] A method for treating a target cancer, comprising administering a bispecific antibody having binding specificity to EGFR and HER3 and a therapeutic agent to the target, wherein the therapeutic agent includes a tyrosine kinase inhibitor (TKI), an alkylating agent, an antimetabolite, a microtubule inhibitor, an anti-cancer antibiotic, a topoisomerase inhibitor, a chemoprotective agent, or a combination thereof.

There is provided a cancer targeting construct comprising a first end and a second end, the first end comprising an IL-13 targeting protein or an IL-13RA2 binding mutant or fragment of IL-13, and the second end comprising an eA5 targeting protein or EphA2, EphA3 and EphB2 binding mutant or fragment of eA5, and an effector molecule coupled to the first end and / or to the second end, wherein the construct is a fusion protein and / or a covalent conjugate. Also provided is a method of treating cancer (e.g., breast cancer) in a subject in need thereof, comprising administering to the subject a construct as taught herein or a composition comprising the construct in a therapeutically effective amount.

The present disclosure relates generally to compositions and methods for treating cancer. More specifically, the present disclosure relates to compositions and their use in one of altering the transformation of epithelial cells to mesenchymal cells or the transformation of mesenchymal cells to epithelial cells of tumor cells. The method comprises administering to the subject a composition comprising a PI3K inhibitor, such as paxalisib (GDC-0084), and an immunotherapy that is not targeted to cancer stem cells (CSC), wherein the immunotherapy is an immune checkpoint antagonist or a PARP inhibitor.

The present disclosure generally relates to cancer therapies and, in some embodiments, to using genetic circuits designed for targeted cancer therapies. The genetic circuit, in some embodiments, utilizes a suitable vector capable of delivering DNA sequences comprising functional units comprising a transcriptional promoter, target sequences and a transcriptional terminator. Together, the genetic circuit, in some embodiments, may trigger apoptosis — a target protein activity where cell death occurs — in cancer cells, and protect non-cancer cells from apoptosis. In some embodiments, the genetic circuit may direct target protein activity in cancer cells, while not directing protein activity in non-cancer cells. However, in the presence of certain stimuli, the inhibition is relieved, which may lead to the induction of target protein activity in cancer cells. In addition, some embodiments are generally directed to vectors comprising a first sequence encoding at least a portion of Mdm2 and a promoter, and a second sequence encoding a promoter and a fusion protein comprising at least a portion of p53 and iCasp-9 (or another protein capable of achieving a therapeutic objective), optionally connected by a linker sequence capable of allowing each protein subunit of the fusion protein to be independently active but subject to the same proteolytic pathways as p53 in cancer and non-cancer cells. Other aspects are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

The present disclosure relates to a cancer-targeting peptide that can be cleaved by cathepsin B in cancer cells and is characterized by forming prodrug nanoparticles together with an anticancer agent, wherein the preparation of carrier-free prodrug nanoparticles may provide a new approach to cancer treatment and may significantly improve cancer targeting and the therapeutic efficacy of an anticancer agent.

A compound derivative is provided, where R in the compound of formula A is (2-(2-(piperidin-1-yl)ethane-1-amine), and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.

Provided herein are methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of ZSCAN4 in cancer cells in the subject, thereby treating the cancer.

This invention relates to compounds of formula I or Ia: (I) (Ia). Y is EuK, —EuAF, —EuPG, -L-EuE; Z is a chelating moiety; and the other substituents are as defined herein. Also provided are formulations comprising such a compound, as well as methods of imaging or methods for the treatment of cancer comprising use of such a compound or formulation.

To provide methods and compositions for sensitization of tumor cells to immune therapy.SOLUTION: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject having cancer) by administering to the subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of composition related to methods of sensitizing a cancer cell to tumor necrosis factor alpha (TNF-α)- mediated killing by contacting the cancer cell or administering an agent that inhibits autophagy. Provided herein are methods and compositions for increasing the sensitivity of cancer cells to T cell killing (e.g., tumor necrosis factor-α (TNF -α)- mediated killing) by inhibiting autophagy and / or the NF-κB pathway.SELECTED DRAWING: None

The application discloses a spiro derivative as a WRN helicase inhibitor and application thereof. The spiro derivative has better WRN helicase inhibiting activity, can be used for inhibiting the growth of microsatellite instability (MSI) tumor cells by inhibiting WRN to cause high levels of DNA double-strand breaks (DSB) in the MSI cells, can be used for preventing and / or treating related cancers, especially colorectal cancer, gastric cancer, ovarian cancer and endometrial tumor, can fill the gap of specific MSI typing cancer targeting drugs, and has very good application prospect and value in the medical field.

In various embodiments human anti-CD46 antibodies that are internalizing and enter tumor cells via the macropinocytosis pathway are provided, as well as antibody-drug conjugates (ADCs) developed from these antibodies for diagnostic and / or therapeutic targeting of CD46-overexpressing tumors.

To provide nucleic acid sequences for targeting one or more point mutations in the p53 gene.SOLUTION: In particular, the sites of the point mutations in p53 are selected from the group consisting of R249, R248, R273 and R175. Also disclosed herein is a method for treating cancer in a subject, the method comprising administering to the subject one or more of the nucleic acid sequences disclosed herein.SELECTED DRAWING: None

The present invention relates generally to antibodies and antigen-binding fragments thereof, in particular those targeting cancer- associated antigens, compositions comprising the same, and methods and uses thereof for detecting cancer-associated antigens in tissues, including prostate cancer tissues. Also provided herein are methods for detecting prostate cancer in a subject, methods for detecting and measuring the severity of prostate cancer in a subject, methods for monitoring the progression of prostate cancer in a subject, methods for determining the likelihood of the presence of prostate cancer in a subject, methods for identifying a subject suffering from prostate cancer who is likely to respond to cancer therapy, methods for predicting the risk of recurrence of prostate cancer in a subject following treatment with a cancer therapy, methods for treating prostate cancer in a subject, methods of stratifying a subject for prostate cancer therapy, uses of anti-cancer agent in the manufacture of a medicament for treating prostate cancer in a subject, and an anti-cancer agent for use in the treatment of prostate cancer in a subject, based upon the detection of specific protein biomarkers with the antibodies described herein. Also contemplated are immunoassays, including immunohistochemistry (IHC) and immunofluorescence (IF), to detect specific protein biomarkers in biological samples. The preferred biomarkers include endosomal proteins, such as Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1), sortilin-1 (SORT1), Syndecan-1 (SDC1).

The application discloses a cancer targeting drug generation method based on differential geometry and reinforcement learning, belongs to the intelligent control technical field, and accurately describes the geometric characteristics of a molecular surface through differential geometry, generates diversified and chemically reasonable molecular conformations through DDPM, expands a molecular library in combination with a genetic algorithm, and optimizes the binding affinity of a molecule and a mutant target protein through reinforcement learning. The cancer targeting drug generation method based on differential geometry and reinforcement learning provided by the application does not need the complex post-processing of traditional methods, has a simple structure, is high in efficiency, and provides a brand-new technical paradigm for cancer targeting drug design.

Provided herein are cancer-targeted nanoparticles for the treatment or prevention of cancer.

Disclosed herein are multivalent, multispecific single-chain antibodies having specificity for four antigens selected from the group consisting of EGFR, PD-L1, HSA, CD28, CD3E, OX-40, CD40, 4-1BB, LAG3, and CD16A.

The invention relates to the technical field of liposome preparation, and particularly discloses an anti-cancer targeted nano-liposome and a preparation method thereof, and the anti-cancer targeted nano-liposome comprises the following components in parts by mass: 1-10 parts of paclitaxel, 50-80 parts of phospholipid, 10-30 parts of cholesterol, 5-15 parts of DSPE-PEG2000, 2-8 parts of folic acid-PEG-DSPE, 1-3 parts of trehalose and 4-6 parts of mannitol. The folic acid ligand in the folic acid-PEG-DSPE can mediate active targeting, so that the intake of cancer cells to the folic acid-PEG-DSPE can be improved; meanwhile, the PEG layer can resist RES phagocytosis, the half-life period of plasma is prolonged, the stability is improved, and the stability of the composition is further improved through a cholesterol enhanced membrane structure.

The present invention relates to recombinant CAR-NK cells or CAR T-cells, expressing a CAR binding to the antigen CLEC12A or a functional alternatively spliced transcript variant thereof, wherein at least one immune checkpoint receptor protein, such as, for example NKG2A, CLEC12A, PD-1, TIM-3, TIGIT and / or KIRS, is inactivated. These highly functional immune checkpoint-inactivated CAR-NK cells or CAR T-cells target cancer-associated antigens or are adapted for a treatment of autoimmune diseases. Furthermore, the present invention relates to a non-virus-based method for producing a CAR-NK cell or CAR T-cell expressing an antigen-targeting chimeric antigen receptor (CAR) and a recombinant CAR-NK cell or CAR T-cell as produced, in particular a CAR- NK cell or CAR T-cell targeting the cancer-associated antigen CLEC12A. The present invention also relates to medical uses of the CAR-NK cell or CAR T-cell. The present invention further relates to a CAR-construct, comprising a modified CD8α or CD28 transmembrane domain.

A cancer neoantigen-expressing cell membrane GRP94-targeting chimeric antigen receptor, comprising a signal peptide region, a cell membrane GRP94-targeting antigen binding domain, a hinge region, a transmembrane domain, and a signal transduction activation domain which are connected in sequence from the amino terminus to the carboxyl terminus, wherein the nucleotide sequence and amino acid sequence of the signal peptide region are as shown in SEQ ID No: 1 and SEQ ID No: 2 respectively; and the antigen binding domain is a portion of an antibody itself that targets cancer neoantigen-expressing cell membrane GRP94, or formed between portions of the antibody itself or between a portion thereof and an antibody region for another target. A novel chimeric antigen receptor (CAR)-engineered NK immune cell and a cancer drug can rapidly induce apoptosis in novel cancer cells having potentially cancer antigen-expressing cell membrane GRP94 protein, generate no toxic and side effects such as cytokine storms, and have off-the-shelf universal applicability, thereby providing a new choice for cell immunotherapy for cancers and also laying a foundation for accurate individualized treatment for cancer treatment.